Excessive exposure may cause fever, chills, nausea, vomiting, mental, confusion, and wheezing. Bleomycin may cause irritation to eyes, skin and respiratory tract. It may also cause a darkening or thickening of the skin. It may cause an allergic reaction.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
Patients with this genotype have reduced survival time and increased frequency of early relapse when using bleomycin to treat testicular cancer.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Bleomycin. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Bleomycin. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bleomycin. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bleomycin. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Bleomycin. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bleomycin. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Bleomycin. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Bleomycin. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Bleomycin. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bleomycin. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Bleomycin. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bleomycin. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bleomycin. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Bleomycin. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bleomycin. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bleomycin. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Bleomycin. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Bleomycin. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Bleomycin. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bleomycin. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Bleomycin. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bleomycin. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Bleomycin. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Bleomycin. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bleomycin. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bleomycin. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Bleomycin. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bleomycin. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Bleomycin. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Bleomycin. |
| Cladribine | Bleomycin may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Bleomycin. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Bleomycin. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Bleomycin is combined with Chlorambucil. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Bleomycin is combined with Raltitrexed. |
| Mitomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Mitomycin. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bleomycin is combined with Bexarotene. |
| Vindesine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Vindesine. |
| Floxuridine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Floxuridine. |
| Indomethacin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Indomethacin. |
| Tioguanine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Tioguanine. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Vinorelbine. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Bleomycin is combined with Dexrazoxane. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Bleomycin is combined with Beclomethasone dipropionate. |
| Sorafenib | The risk or severity of adverse effects can be increased when Bleomycin is combined with Sorafenib. |
| Streptozocin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Streptozocin. |
| Trifluridine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Trifluridine. |
| Betamethasone | The risk or severity of adverse effects can be increased when Bleomycin is combined with Betamethasone. |
| Teniposide | The risk or severity of adverse effects can be increased when Bleomycin is combined with Teniposide. |
| Epirubicin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Epirubicin. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Bleomycin is combined with Chloramphenicol. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Bleomycin is combined with Lenalidomide. |
| Altretamine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Altretamine. |
| Zidovudine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Zidovudine. |
| Cisplatin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Cisplatin. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Oxaliplatin. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Bleomycin is combined with Cyclophosphamide. |
| Vincristine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Vincristine. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluorouracil. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Bleomycin is combined with Propylthiouracil. |
| Pentostatin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Pentostatin. |
| Methotrexate | The risk or severity of adverse effects can be increased when Bleomycin is combined with Methotrexate. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Carbamazepine. |
| Vinblastine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Vinblastine. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluticasone propionate. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluocinolone acetonide. |
| Linezolid | The risk or severity of adverse effects can be increased when Bleomycin is combined with Linezolid. |
| Imatinib | The risk or severity of adverse effects can be increased when Bleomycin is combined with Imatinib. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Bleomycin is combined with Triamcinolone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Clofarabine. |
| Prednisone | The risk or severity of adverse effects can be increased when Bleomycin is combined with Prednisone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Bleomycin is combined with Pemetrexed. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Bleomycin is combined with Fludrocortisone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Bleomycin is combined with Mycophenolate mofetil. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Daunorubicin. |
| Tretinoin | The risk or severity of cardiotoxicity can be increased when Bleomycin is combined with Tretinoin. |
| Irinotecan | The risk or severity of adverse effects can be increased when Bleomycin is combined with Irinotecan. |
| Methimazole | The risk or severity of adverse effects can be increased when Bleomycin is combined with Methimazole. |
| Etoposide | The risk or severity of adverse effects can be increased when Bleomycin is combined with Etoposide. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Sulfasalazine. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Dacarbazine. |
| Temozolomide | The risk or severity of adverse effects can be increased when Bleomycin is combined with Temozolomide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Penicillamine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Bleomycin is combined with Prednisolone. |
| Sirolimus | The risk or severity of adverse effects can be increased when Bleomycin is combined with Sirolimus. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Mechlorethamine. |
| Azacitidine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Azacitidine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Carboplatin. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Bleomycin is combined with Methylprednisolone. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Dactinomycin. |
| Cytarabine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Cytarabine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Azathioprine. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Doxorubicin. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Bleomycin is combined with Hydroxyurea. |
| Busulfan | The risk or severity of adverse effects can be increased when Bleomycin is combined with Busulfan. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Bleomycin is combined with Mycophenolic acid. |
| Topotecan | The risk or severity of adverse effects can be increased when Bleomycin is combined with Topotecan. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Bleomycin is combined with Mercaptopurine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Bleomycin is combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Bleomycin is combined with Melphalan. |